Literature DB >> 22721497

Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia.

Olga Blau1, Rimma Berenstein, Annette Sindram, Igor Wolfgang Blau.   

Abstract

Mutation of the FMS-like tyrosine kinase-3 (FLT3) gene occurs with a frequency of 20-25% in acute myeloid leukemia (AML). Different studies have reported conflicting results, stating the importance of the length, position and number of internal tandem duplications (ITDs) for prognostic significance. In the present study, FLT3-ITD mutations were found in 51 (23%) of 218 patients with AML. Using sequence analysis we categorized ITD integration sites according to functional regions of the FLT3 receptor. Median ITD size was 61 bp. The insertion site was strongly correlated with ITD size: more C-terminal located inserted fragments were significantly bigger. Our data confirm that FLT3-ITD mutations identify a subset of young patients with AML with normal cytogenetics but with inferior outcome. Patients with AML with mutation localization outside the juxtamembrane domain showed no correlation with worse prognosis. A high mutant/wild-type ratio appears to have a major impact on the prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721497     DOI: 10.3109/10428194.2012.704999

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Authors:  T Fischer; F H Heidel; P Arreba-Tutusaus; T S Mack; L Bullinger; T M Schnöder; A Polanetzki; S Weinert; A Ballaschk; Z Wang; A J Deshpande; S A Armstrong; K Döhner
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

2.  A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.

Authors:  Yi Zhang; Bi-De Zhao; Cheng-Cheng Wang; Yun-Gui Wang; Hua-Feng Wang; Jing-Han Wang; Li-Xia Liu; Feng Lou; Shan-Bo Cao; Xiao-Xia Hu; Ai-Jie Huang; Jian-Min Yang; Hai-Tao Meng; Wen-Juan Yu; Hong-Yan Tong; Jian-Min Wang; Jie Jin
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 4.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 5.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

6.  Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.

Authors:  Fang Chen; Junya Sun; Changxin Yin; Jiaying Cheng; Jinle Ni; Ling Jiang; Qiang Wang; Guopan Yu; Yongqiang Wei; Xiaoli Liu; Jing Sun; Bing Z Carter; Xuejie Jiang
Journal:  Bone Marrow Transplant       Date:  2019-10-23       Impact factor: 5.483

7.  Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Authors:  Rimma Berenstein; Igor Wolfgang Blau; Nikola Suckert; Claudia Baldus; Antonio Pezzutto; Bernd Dörken; Olga Blau
Journal:  J Exp Clin Cancer Res       Date:  2015-05-22

Review 8.  Molecular Genetic Markers in Acute Myeloid Leukemia.

Authors:  Sophia Yohe
Journal:  J Clin Med       Date:  2015-03-12       Impact factor: 4.241

Review 9.  Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis.

Authors:  Rimma Berenstein
Journal:  Biomark Insights       Date:  2015-08-05

10.  Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.

Authors:  Adhra Al-Mawali; David Gillis; Ian Lewis
Journal:  J Hematol Oncol       Date:  2016-07-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.